

U.S. Food and Drug Administration
 Protecting and Promoting *Your* Health

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

f [SHARE \(HTTPS://WWW.FACEBOOK.COM/SHARER/SHARER.PHP?U=HTTP://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/OB/PATENT_INFO.CFM?PRODUCT_NO=001&APPL_NO=022511&APPL_TYPE=N\)](https://www.facebook.com/sharer/sharer.php?u=http://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?product_no=001&appl_no=022511&appl_type=N)

🐦 [TWEET \(HTTPS://TWITTER.COM/INTENT/TWEET/?TEXT=ORANGE BOOK: APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS&URL=HTTP://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/OB/PATENT_INFO.CFM?PRODUCT_NO=001&APPL_NO=022511&APPL_TYPE=N\)](https://twitter.com/intent/tweet?text=Orange%20Book:%20Approved%20Drug%20Products%20with%20Therapeutic%20Equivalence%20Evaluations&url=http://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?product_no=001&appl_no=022511&appl_type=N)

±

✉ [EMAIL \(MAILTO:?SUBJECT=ORANGE BOOK: APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS&BODY=HTTP://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/OB/PATENT_INFO.CFM?PRODUCT_NO=001&APPL_NO=022511&APPL_TYPE=N\)](mailto:?subject=Orange%20Book:%20Approved%20Drug%20Products%20with%20Therapeutic%20Equivalence%20Evaluations&body=http://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?product_no=001&appl_no=022511&appl_type=N)

[Home \(default.cfm?resetfields=1\)](#) | [Back to Product Details](#)

Additional Information about Patents

- Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
- Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. These patents may not be flagged with respect to other claims which may apply.

Patent and Exclusivity for: N022511

Product 001
 ESOMEPRAZOLE MAGNESIUM; NAPROXEN (VIMOVO) TABLET, DELAYED RELEASE EQ
 20MG BASE;500MG

Patent Data

Product No	Patent No	Patent Expiration	Drug Substance Claim	Drug Product Claim	Patent Use Code	Delist Requested
001	5714504*PED	Aug 3, 2015			(show_code.cfm?id=&type=0)	

Product No	Patent No	Patent Expiration	Drug Substance Claim	Drug Product Claim	Patent Use Code	Delist Requested
001	5900424	May 4, 2016	DS		<u>U-1053</u> <u>(show_code.cfm?id=1156&type=0)</u>	
001	5900424*PED	Nov 4, 2016			<u>(show_code.cfm?id=&type=0)</u>	
001	6369085	May 25, 2018	DS	DP	<u>U-1053</u> <u>(show_code.cfm?id=1156&type=0)</u>	
001	6369085*PED	Nov 25, 2018			<u>(show_code.cfm?id=&type=0)</u>	
001	6926907	Feb 28, 2023		DP	<u>U-1052</u> <u>(show_code.cfm?id=1155&type=0)</u>	
001	7411070	May 25, 2018	DS		<u>U-1053</u> <u>(show_code.cfm?id=1156&type=0)</u>	
001	7411070*PED	Nov 25, 2018			<u>(show_code.cfm?id=&type=0)</u>	
001	7745466	Oct 13, 2018		DP	<u>U-1053</u> <u>(show_code.cfm?id=1156&type=0)</u>	
001	8557285	May 31, 2022		DP	<u>(show_code.cfm?id=&type=0)</u>	
001	8852636	May 31, 2022		DP	<u>U-1052</u> <u>(show_code.cfm?id=1155&type=0)</u>	
001	8858996	May 31, 2022		DP	<u>U-1052</u> <u>(show_code.cfm?id=1155&type=0)</u>	
001	8945621	Oct 17, 2031			<u>U-1661</u> <u>(show_code.cfm?id=1638&type=0)</u>	

Product No	Exclusivity Code	Drug	Exclusivity Expiration	Delist Requested
Product No	Patent No	Substance Claim	Product Claim	Patent Use Code
001	9161920		May 31, 2022	<u>U-1760</u> <u>(show_code.cfm?id=1728&type=0)</u>
001	9198888		May 31, 2022	<u>U-1781</u> <u>(show_code.cfm?id=1736&type=0)</u>
001	9220698		Mar 10, 2031	<u>U-1781</u> <u>(show_code.cfm?id=1736&type=0)</u>
001	9345695		May 31, 2022	DP <u>(show_code.cfm?id=&type=0)</u>
001	9393208		Sep 3, 2029	<u>U-1781</u> <u>(show_code.cfm?id=1736&type=0)</u>

Exclusivity Data

Product No	Exclusivity Code	Exclusivity Expiration
------------	------------------	------------------------

There is no unexpired exclusivity for this product in the Orange Book database.

[View a list of all patent use codes \(results_patent.cfm\)](#)

[View a list of all exclusivity codes \(results_exclusivity.cfm\)](#)